In this study, we report that p53 acetylation is a favorable prognostic marker for GBM, regardless of p53 status, and is regulated by Smad1, an intracellular effector of bone morphogenetic proteins (BMPs) signaling, in a p300‐dependent manner. This evidence concerns the gene SMAD1 and glioblastoma.